Ask an Expert
US pharmaceutical major Eli Lilly and Company has announced plans to invest more than US $1 billion in India in the next few years to significantly expand its manufacturing and supply capabilities. The investment will focus on collaborating with local contract drugmakers rather than building wholly owned plants, tapping into India’s skilled pharmaceutical workforce and established supply base. This strategy is aimed at strengthening Lilly’s global manufacturing network and ensuring reliable production of key medicines for conditions such as obesity, diabetes, cancer, Alzheimer’s and autoimmune diseases.
A major part of the plan is to establish a new manufacturing and quality oversight hub in Hyderabad, which will serve as a central point for Lilly’s contract manufacturing operations in the country and help maintain global quality standards. The expansion is expected to boost the availability of Lilly’s treatments in India and abroad while creating skilled jobs in areas like engineering, chemistry, quality control and analytics. India does not currently host a Lilly-owned manufacturing facility, but several Indian firms already produce complex drugs and injectables for global pharma companies under contract. The move highlights India’s growing importance as a manufacturing hub in the global healthcare supply chain and aligns with broader trends of pharmaceutical firms diversifying production locations.
